Team
Isosceles has assembled a team with decades of experience in successfully developing FDA-approved parenteral pain products from intravenous and surgical site injectables to transdermal patches and sublingual tablets. Our team has a singular focus: to create a rapid onset non-opioid/non-NSAID product with fast onset and long acting analgesia.
Chief Executive Officer
William Humphries is an exceptional leader that embodies the ability to develop and implement overall strategies to deliver results. High performing and experienced executive professional with more than 33 years of background and knowledge leading specialty pharmaceutical industry companies as President of Ortho-Dermatologics (a Bausch Health Company), Chief Executive Officer at Merz, President Stiefel (a GSK company), and Vice President Sales and Marketing at Allergan. Significant business acumen and the ability to manage high levels of stress without comprising judgment in key decision-making activities.
President
Brett Lanier is a medicinal chemist with over a decade of experience in the pharmaceutical industry and founding member of Isosceles Pharmaceuticals. His background includes extensive knowledge around the chemical synthesis and pharmaceutical scale GMP manufacturing of synthetic Cannabinoids and controlled substances. He has worked within the medical device, clinical research, and pharmaceutical contract manufacturing industry with branded and 505(b)(2) branded generic customers at all levels of drug development from pre-formulation, early and late phase trials and commercial launch post FDA approval.
Executive Chairman of the Board
Tim Wright is a highly accomplished executive with a 30-year track record of building, transforming and positioning pharmaceutical organizations for continued growth across highly competitive markets. A visionary, focused leader recognized for creating value and improving quality of life leveraging his extensive experience in pain management and inflammatory diseases. Wright has achievements leading full lifecycle development of novel therapeutic modalities, from conception through commercialization and growth across North America, Europe and Asia.
Senior Medical Advisor & Member Board of Directors
Robert Stein, a Duke University Graduate School alumni, has a strong background in a wide ranging expertise from drug discovery, clinical research, development and trials in biopharmaceuticals and oncology. Robert served as Executive Director and Head of Pharmacology at Merck Sharp & Dohm, SVP of R&D and CSO for Ligand Pharmaceuticals, and EVP of Research & Pre-Clinical Development Dupont-Merck Pharmaceuticals. He also served as President of Incyte, Roche and CEO of KineMed, Inc. as well as a Senior Advisor of R&D at Agenus, Inc. and is an Operating Partner at Samsara BioCapital.
Chief Strategy Officer
Deborah Mosca is a proven leader of multi‐disciplinary drug development project teams with the ability to anticipate risks and implement creative solutions to meet project timelines and budgets. She has guided the discovery and development of novel therapeutic agents for human, animal, and agricultural applications in various organizations including biotech, non-profit research institutions, and large Pharma. In her previous role as Chairman and Chief Executive Officer of the Marine Bio-Technologies Center of Innovation, Deborah was responsible for creating the business strategy to drive the commercialization of marine biotechnologies from North Carolina's vast network of premier marine research institutions. At PaxVax, she provided strategic leadership for vaccine development programs and assisted with revenue generation through contracts, licensing, corporate partnerships, and venture capital activities. While at The Scripps Research Institute, Deborah coordinated efforts for the IBM-TSRI Consortium for Project Checkmate (a proactive approach to avian flu) and joined Governor Jeb Bush in meetings with Roche and Novartis to stimulate international economic development in Florida.
Medical Advisor
Mike Royal is a senior pharmaceutical executive with over 30 years’ experience in the drug development process with expertise in clinical research and medical and regulatory affairs. He has been responsible for clinical trial oversight from phase 1 through phase 4, including multi-site/multi-country trials and has an established track record for innovative solutions to development obstacles. Mike has been instrumental in setting product launch and lifecycle management strategies and successfully submitted NCE and 505(b)(2) NDAs across several indications as well as ANDAs.. He is board-certified in internal medicine, anesthesiology, pain management and addiction medicine and has over 190 peer-reviewed publications, book chapters and abstracts/posters.
Regulatory Affairs Strategy
Mark Mannebach has over 30 years of experience in the pharmaceutical industry in Regulatory Affairs with extensive knowledge of Quality Assurance, Program Management, and Pharmaceutical Science. During his career, he has filed numerous NDA’s, BLA’s, PME’s, ANDA’s and 505(b)(2) submissions. Mark has assisted with the development of branded and specialty pharmaceuticals as well as biologics for many therapeutic applications including ophthalmology, pain management, neurology/CNS, and anti-inflammation.